Rob Base raps over a remixed version of his hit song 'It Takes Two' in Eli Lilly and Boehringer Ingelheim's latest CKD campaign.

November 1, 2023 08:00 AM EDT

Marketing

Eli Lilly and Boehringer Ingelheim pay tribute to hip-hop anniversary in chronic kidney disease campaign with Rob Base

Nicole DeFeudis

Editor

“It takes two” to make diagnoses of chronic kidney disease go right, Eli Lilly and Boehringer Ingelheim suggest in their latest campaign featuring hip-hop artist …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly and Boehringer Ingelheim pay tribute to hip-hop anniversary in chronic kidney disease campaign with Rob Base

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Eli Lil­ly and Boehringer In­gel­heim pay trib­ute to hip-hop an­niver­sary in chron­ic kid­ney dis­ease cam­paign with Rob Base

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Eli Lilly and Boehringer Ingelheim pay tribute to hip-hop anniversary in chronic kidney disease campaign with Rob Base

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?